Major Depressive Disorder Clinical Trials

96 studies are recruiting for major depressive disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

2. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

   X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   IMA Clinical Research Phoenix, Phoenix, Arizona

   Locations

   51 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT06775379 on ClinicalTrials.gov

3. DBS for Depression

   The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demons…

   Stage

   Not phased

   Ages

   22 to 70

   Site

   University of Texas Southwestern, Dallas, Texas

   Locations

   2 in total

   Run by

   Baylor College of Medicine

   See if you can join NCT03437928 on ClinicalTrials.gov

4. Mindful Self-Compassion for Anxiety Disorders and Depression

   The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or …

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Run by

   Georgetown University

   See if you can join NCT05671419 on ClinicalTrials.gov

5. A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   NoesisPharma, LLC, Phoenix, Arizona

   Locations

   32 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT07115329 on ClinicalTrials.gov

6. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Huntsville, Alabama

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

7. A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Oceanside, California

   Locations

   60 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07196501 on ClinicalTrials.gov

8. A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

   The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, sel…

   Stage

   Phase 2

   Ages

   21 to 65

   Site

   The Ohio State University Department of Psychiatry, Columbus, Ohio

   Run by

   Ohio State University

   See if you can join NCT06820723 on ClinicalTrials.gov

9. RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

   In this research study, investigators examine how brain activity changes during tests of emotional processing, attention, and memory using multimodal neuroimaging methods including electroencephalography (EEG), functional magnetic resonance imaging (fMRI), and functional near-infrared spectroscopy …

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Medical Univeristy of South Carolina, Charleston, South Carolina

   Run by

   Medical University of South Carolina

   See if you can join NCT05977439 on ClinicalTrials.gov

10. Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

    Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Acacia Clinics, Sunnyvale, California

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06376734 on ClinicalTrials.gov

11. Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

    This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depress…

    Stage

    Not phased

    Ages

    10 to 24

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    2 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05437588 on ClinicalTrials.gov

12. Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

    This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minu…

    Stage

    Not phased

    Ages

    24 to 65

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07111390 on ClinicalTrials.gov

13. CARED : A Novel Rapid Treatment Paradigm for Depression

    The purpose of this study is to primarily assess the feasibility and secondarily assess the efficacy of a single session intervention (SSI) that combines non-invasive brain stimulation and psychotherapy for Major Depressive Disorder (MDD). investigators will recruit 30 people with MDD, with at leas…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    Carolina Center for Neurostimulation, Chapel Hill, North Carolina

    Run by

    University of North Carolina, Chapel Hill

    See if you can join NCT07507370 on ClinicalTrials.gov

14. DBS for TRD With the Medtronic Percept PC

    Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which…

    Stage

    Not phased

    Ages

    25 to 70

    Site

    Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, New York

    Run by

    Helen Mayberg, MD

    See if you can join NCT05773755 on ClinicalTrials.gov

15. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, ti…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Harmonex /ID# 277517, Dothan, Alabama

    Locations

    33 in total

    Run by

    AbbVie

    See if you can join NCT07276997 on ClinicalTrials.gov

16. Evaluating tDCS Brain-stimulation in Depression Using MRI

    Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific …

    Stage

    Not phased

    Ages

    20 to 55

    Site

    University of California Los Angeles (UCLA), Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05598034 on ClinicalTrials.gov

17. Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback

    The purpose of this study is to develop a technique called real time fMRI neurofeedback. This technique uses a regular MRI scanner, except that special software allows the researchers to measure activity in participants brain, using fMRI, and then give information, in the form of a feedback signal,…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    University of Michigan, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT06050070 on ClinicalTrials.gov

18. tDCS: Sleep to Mood in Depression (S2M-D)

    The purpose of this study is to determine whether changes in sleep consolidation occur during home-based transcranial direct current stimulation (tDCS) in adults with moderate depression and whether these changes are temporally associated with improvements in depressive symptoms.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07572526 on ClinicalTrials.gov

19. Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

    The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 …

    Stage

    Not phased

    Ages

    18 to 64

    Site

    University of Illinois at Chicago, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT05051618 on ClinicalTrials.gov

20. Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

    The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).

    Stage

    EARLY_Phase 1

    Ages

    18 to 65

    Site

    Emory University, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT05327699 on ClinicalTrials.gov

21. Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

    The goal of this clinical trial is to learn how different types of non-invasive brain stimulation affect mood and brain function in adults with major depressive disorder (MDD). It will also study how brain stimulation may work together with antidepressant treatments. The main questions this study a…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Bellefield Towers, Pittsburgh, Pennsylvania

    Run by

    Marta Peciña, MD PhD

    See if you can join NCT06976840 on ClinicalTrials.gov

22. Triage Survey for Psychiatry Research Eligibility

    TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Adams Clinical, Boston, Boston, Massachusetts

    Locations

    6 in total

    Run by

    Adams Clinical

    See if you can join NCT05800925 on ClinicalTrials.gov

23. Neural Correlates of Stress and Perceived Control in Adolescent Depression

    Lack of perceived control, particularly during stress, has been critically implicated in major depressive disorder (MDD) and anhedonic symptoms, especially among female adolescents; yet the neural underpinnings of perceived control disruptions in MDD remain poorly understood. Using functional magne…

    Stage

    Not phased

    Ages

    14 to 18

    Site

    McLean Hospital, Belmont, Massachusetts

    Run by

    Mclean Hospital

    See if you can join NCT04788524 on ClinicalTrials.gov

24. Aβ Dynamics in LLMD

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and as…

    Stage

    Phase 4

    Ages

    60 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05004987 on ClinicalTrials.gov

25. The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

    The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).

    Stage

    Phase 2

    Ages

    21 to 65

    Site

    VA Connecticut Healthcare System, West Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT05786066 on ClinicalTrials.gov